Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for AMRN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 6.124M
March 31, 2026 -8.284M
December 31, 2025 -3.540M
September 30, 2025 -12.29M
June 30, 2025 12.57M
March 31, 2025 12.11M
December 31, 2024 -22.75M
September 30, 2024 -56.67M
June 30, 2024 4.722M
March 31, 2024 28.70M
December 31, 2023 -71.30M
September 30, 2023 30.87M
June 30, 2023 34.59M
March 31, 2023 -19.79M
December 31, 2022 -25.84M
September 30, 2022 29.82M
June 30, 2022 72.71M
March 31, 2022 98.48M
December 31, 2021 24.82M
September 30, 2021 -99.44M
June 30, 2021 50.34M
March 31, 2021 128.37M
December 31, 2020 22.42M
September 30, 2020 -5.342M
June 30, 2020 -102.97M
Date Value
March 31, 2020 -294.01M
December 31, 2019 -0.3713M
September 30, 2019 -1.314M
June 30, 2019 -0.8034M
March 31, 2019 0.00
December 31, 2018 -0.0049M
September 30, 2018 -0.053M
June 30, 2018 0.00
March 31, 2018 0.00
December 31, 2017 0.00
September 30, 2017 -0.0001M
June 30, 2017 -0.0006M
March 31, 2017 -0.0115M
December 31, 2016 -0.0005M
September 30, 2016 -0.0003M
June 30, 2016 -0.0003M
March 31, 2016 -0.0197M
December 31, 2015 -0.018M
September 30, 2015 -0.0099M
June 30, 2015 0.00
March 31, 2015 0.00
December 31, 2014 0.00
September 30, 2014 0.00
June 30, 2014 0.00
March 31, 2014 0.00

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Neurocrine Biosciences, Inc. -135.40M
Alkermes Plc -2.411M
Cellectis SA 18.75M
Akari Therapeutics Plc 0.00
Liquidia Corp. -12.24M